Catalent agrees to sell Blow-Fill-Seal business
SK Capital expected to take ownership of CDMO business in April
SK Capital Partners LP, a private equity firm that focuses on the specialty materials, chemicals and pharma sectors, has signed an agreement to acquire the Blow-Fill-Seal (BFS) sterile contract development and manufacturing business from Catalent Pharma Solutions, LLC.
The deal is expected to close in April 2021, which is when the contract development and manufacturing organization (CDMO) will function as an independent company.
The BFS business’ primary focus is clinical to commercial stage formulation and manufacturing. It is catered toward an international, blue-chip customer base with products that use its BFS sterile manufacturing capabilities and formulation know-how in small molecule, biologics, macromolecules and potent compounds.
